|
|
Volumn 33, Issue 7-8, 2001, Pages 3606-3607
|
|
Experience with Basiliximab in pediatric liver graft recipients
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CYCLOSPORIN;
INTERLEUKIN 2 RECEPTOR;
INTERLEUKIN 2 RECEPTOR ANTIBODY;
METHYLPREDNISOLONE;
PREDNISOLONE;
TACROLIMUS;
ARTICLE;
ATRESIA;
CALCULATION;
CELL ACTIVATION;
CELL PROLIFERATION;
CHILD;
CLINICAL FEATURE;
CLINICAL TRIAL;
COHORT ANALYSIS;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DONOR;
GRAFT REJECTION;
HELPER CELL;
HISTOLOGY;
HUMAN;
HYPERTENSION;
IMMUNOSUPPRESSIVE TREATMENT;
INCIDENCE;
INFECTION;
INFORMED CONSENT;
INTRAHEPATIC CHOLESTASIS;
LIVER BIOPSY;
LIVER TRANSPLANTATION;
MAJOR CLINICAL STUDY;
NEPHROTOXICITY;
NEWBORN HEPATITIS;
OLIGURIA;
POSTOPERATIVE CARE;
PRIORITY JOURNAL;
ACUTE DISEASE;
ANTIBODIES, MONOCLONAL;
BODY WEIGHT;
CHILD;
CHILD, PRESCHOOL;
CYCLOSPORINE;
DOSE-RESPONSE RELATIONSHIP, DRUG;
DRUG MONITORING;
DRUG THERAPY, COMBINATION;
GRAFT REJECTION;
HUMANS;
HYPERTENSION;
IMMUNOSUPPRESSIVE AGENTS;
INFANT;
KIDNEY;
LIVER TRANSPLANTATION;
POSTOPERATIVE COMPLICATIONS;
PREDNISOLONE;
RECOMBINANT FUSION PROTEINS;
|
|
EID: 0035679770
PISSN: 00411345
EISSN: None
Source Type: Journal
DOI: 10.1016/S0041-1345(01)02551-9 Document Type: Article |
|
Times cited : (5)
|
|
References (10)
|
